Patents by Inventor Arthur M. Krieg

Arthur M. Krieg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030139364
    Abstract: The invention involves administration of an imidazoquinoline agent in combination with another therapeutic agent. The combination of drugs may be administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs. The combinations can be used to enhance ADCC, stimulate immune responses and/or patient and treat certain disorders.
    Type: Application
    Filed: October 15, 2002
    Publication date: July 24, 2003
    Applicant: University of Iowa Research Foundation
    Inventors: Arthur M. Krieg, Christian Schetter, Robert L. Bratzler, Jorg Vollmer, Marion Jurk, Stefan Bauer
  • Publication number: 20030100527
    Abstract: The present invention relates generally to methods and products for activating dendritic cells. In particular, the invention relates to oligonucleotides which have a specific sequence including at least one unmethylated CpG dinucleotide which are useful for activating dendritic cells. The methods are useful for in vitro, ex-vivo, and in vivo methods such as cancer immunotherapeutics, treatment of infectious disease and treatment of allergic disease.
    Type: Application
    Filed: June 3, 2002
    Publication date: May 29, 2003
    Applicant: The University of Iowa Research Foundation
    Inventors: Arthur M. Krieg, Gunther Hartmann
  • Publication number: 20030091599
    Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
    Type: Application
    Filed: November 20, 2002
    Publication date: May 15, 2003
    Applicant: Coley Pharmaceutical GmbH
    Inventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
  • Publication number: 20030050263
    Abstract: Oligonucleotides containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. In particular, methods for treating HIV infection are disclosed.
    Type: Application
    Filed: August 16, 2001
    Publication date: March 13, 2003
    Applicant: The University of Iowa Research Foundation
    Inventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
  • Publication number: 20030050268
    Abstract: The invention provides methods and compositions for using immunostimulatory nucleic acids to treat non-allergic inflammatory diseases. Non-allergic inflammatory diseases that may be treated according to the methods and products of the invention include psoriasis and inflammatory bowel disease. The invention further provides methods for augmenting a Th1 response to immunostimulatory nucleic acid involving inhibition of prostaglandin-mediated counter-regulatory response.
    Type: Application
    Filed: March 29, 2002
    Publication date: March 13, 2003
    Inventors: Arthur M. Krieg, Daniel J. Berg
  • Publication number: 20030050261
    Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.
    Type: Application
    Filed: March 27, 2001
    Publication date: March 13, 2003
    Inventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
  • Publication number: 20030026782
    Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and inmmunoinhibitory oligonucleotides for use as antiviral therapeutics.
    Type: Application
    Filed: October 8, 1999
    Publication date: February 6, 2003
    Inventor: ARTHUR M. KRIEG
  • Publication number: 20020164341
    Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
    Type: Application
    Filed: December 18, 2001
    Publication date: November 7, 2002
    Applicant: Loeb Health Research Institute at the Ottawa Hospital
    Inventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
  • Patent number: 6429199
    Abstract: The present invention relates generally to methods and products for activating dendritic cells. In particular, the invention relates to oligonucleotides which have a specific sequence including at least one unmethylated CpG dinucleotide which are useful for activating dendritic cells. The methods are useful for in vitro, ex-vivo, and in vivo methods such as cancer immunotherapeutics, treatment of infectious disease and treatment of allergic disease.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: August 6, 2002
    Assignee: University of Iowa Research Foundation
    Inventors: Arthur M. Krieg, Gunther Hartmann
  • Patent number: 6406705
    Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: June 18, 2002
    Assignees: University of Iowa Research Foundation, Coley Pharmaceutical GmbH, Ottawa Health Research Institute
    Inventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
  • Publication number: 20020064515
    Abstract: The present invention relates to synergistic combinations of immunostimulatory CpG oligonucleotides and immunopotentiating cytokines. In particular, the invention relates to methods of stimulating an immune response using the synergistic combination of compounds and products related thereto.
    Type: Application
    Filed: April 2, 2001
    Publication date: May 30, 2002
    Inventors: Arthur M. Krieg, George Weiner
  • Patent number: 6339068
    Abstract: The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immunostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: January 15, 2002
    Assignees: University of Iowa Research Foundation, Loeb Health Research Institute at the Ottawa Hospital, Coley Pharmaceutical GmbH
    Inventors: Arthur M. Krieg, Heather L. Davis, Tong Wu, Joachim Schorr
  • Patent number: 6239116
    Abstract: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful a synthetic adjuvant.
    Type: Grant
    Filed: October 30, 1997
    Date of Patent: May 29, 2001
    Assignees: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Arthur M. Krieg, Joel N. Kline
  • Patent number: 6218371
    Abstract: The present invention relates to synergistic combinations of immunostimulatory CpG oligonucleotides and immunopotentiating cytokines. In particular, the invention relates to methods of stimulating an immune response using the synergistic combination of compounds and products related thereto.
    Type: Grant
    Filed: April 2, 1999
    Date of Patent: April 17, 2001
    Assignee: University of Iowa Research Foundation
    Inventors: Arthur M. Krieg, George Weiner
  • Patent number: 6214806
    Abstract: The present invention is based on the finding that nucleic acids containing at least one unmethylated cytosine-guanine (CpG) dinucleotide affect immune responses in a subject. These nucleic acids containing at least one unmethylated cytosine-guanine (CpG) dinucleotide can be used to treat pulmonary disorders having an immunologic component, such as a response to inhaled lipopolysaccharide. The invention provides methods of treating subjects who have or are at risk of having these pulmonary disorders, and methods of altering the immunological components of the pulmonary disorders. The invention also provides pharmaceutical compositions for treating pulmonary disorders that have an immunologic component.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: April 10, 2001
    Assignee: University of Iowa Research Foundation
    Inventors: Arthur M. Krieg, David A. Schwartz
  • Patent number: 6207646
    Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: March 27, 2001
    Assignees: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
  • Patent number: 6194388
    Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.
    Type: Grant
    Filed: February 7, 1995
    Date of Patent: February 27, 2001
    Assignees: The University of Iowa Research Foundation, The United States of America, Coley Pharmaceutical Group
    Inventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
  • Patent number: 6008200
    Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.
    Type: Grant
    Filed: February 7, 1995
    Date of Patent: December 28, 1999
    Assignee: University of Iowa Research Foundation
    Inventor: Arthur M. Krieg